EPITHELIAL OVARIAN CANCER

This study tests a new drug combination (carboplatin plus mirvetuximab soravtansine) given before surgery to people with advanced ovarian, fallopian tube, or peritoneal cancer that has a specific protein (FRα). The goal is to see if the treatment shrinks tumors enough to improve …

This study is testing whether adding a blood thinner called tinzaparin to standard chemotherapy can help fight advanced ovarian cancer. Researchers will measure changes in a tumor marker (CA-125) and other blood factors in 40 women with stage III-IV disease. The goal is to see if…

This early-phase study tests a new drug called azenosertib (ZN-c3) combined with standard chemotherapy or bevacizumab in people with ovarian, peritoneal, or fallopian tube cancer that has stopped responding to platinum-based treatment. The main goals are to find safe doses and ch…

This study is for people with advanced ovarian cancer who are scheduled for surgery. It tests whether taking a drug called olaparib alone or with another drug called durvalumab for a short time before surgery is safe and practical. The goal is to see if this approach can be done …

This study tests if removing lymph nodes near the liver (hepato-celiac lymphadenectomy) can help control advanced or recurrent ovarian cancer. About 94 women with stage III/IV or platinum-sensitive recurrent ovarian cancer will have this surgery. The main goal is to see how many …

This study tests whether adding daphnetin capsules to standard chemotherapy and targeted therapy can help control advanced ovarian cancer after initial surgery. About 98 participants with stage III-IV ovarian cancer will receive the treatment and be monitored for side effects and…

This study tests a new treatment using specially engineered immune cells (CAR-NK cells) that target two cancer markers at once. It is for people with ovarian, peritoneal, or fallopian tube cancer that has come back or not responded to at least two prior treatments. The therapy is…

This study tests a new oral drug, AVZO-021, in people with advanced solid tumors that have not responded to other treatments. The drug targets a protein called CDK2 to slow or stop cancer growth. The trial has two phases: first to find the safest dose, then to see if it shrinks t…

This early-phase trial tests a personalized vaccine made from a patient's own tumor cells. The vaccine is designed to train the immune system to recognize and attack ovarian cancer. The study involves 10 women with advanced ovarian cancer who will receive the vaccine alongside st…

This early-stage study tests a new treatment for ovarian cancer that has come back after standard therapy. The treatment uses a patient's own immune cells, which are modified in a lab to better recognize and attack cancer cells. The main goal is to find a safe dose and understand…

This study tests whether a daily pill called isoquercetin (a natural compound found in fruits) can reduce blood markers linked to dangerous clots in people with ovarian cancer. About 90 participants receiving first-line chemotherapy will take either isoquercetin or a placebo for …

This phase 3 trial tests whether adding the experimental drug IMNN-001 to standard chemotherapy improves survival in people with advanced ovarian, fallopian tube, or primary peritoneal cancer. About 500 newly diagnosed participants will receive either the combination or chemother…

This study tests a new drug called ETX-19477 in people with advanced solid tumors (like breast, ovarian, or prostate cancer) that have stopped responding to standard treatments. The goal is to find the safest dose and see if the drug can shrink tumors or slow their growth. About …

This study tests a drug called TORL-1-23 in 230 women with advanced ovarian, fallopian tube, or peritoneal cancer that no longer responds to platinum chemotherapy and has a specific marker (claudin 6). The goal is to see if the drug can shrink tumors and how safe it is. Participa…

This early-phase study tests an experimental treatment called 27T51, a type of CAR T cell therapy that targets a protein (MUC16) found on certain cancer cells. It is for women with recurrent or hard-to-treat ovarian, peritoneal, or fallopian tube cancer. The study has two parts: …

This phase 3 trial tests whether the experimental drug BL-B01D1 works better than standard chemotherapy for people with ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to platinum-based treatment. About 384 adults who have had 1-3 prior treatment…

This study tests a new drug, AZD5335, against current standard treatments for women with a tough-to-treat type of ovarian cancer that has stopped responding to platinum chemotherapy. About 1,100 women with high or low levels of a protein called FRα will be randomly assigned to re…

This study tests a new imaging agent called [18F]FPyQCP for PET scans to detect five types of cancer: colorectal, ovarian, gastric, invasive lobular breast, and pancreatic. About 71 adults will receive a single dose of the agent to check its safety and how well it finds cancer, e…

This study looks at whether a program of exercise and nutrition during chemotherapy can help elderly patients (65+) with ovarian or pancreatic cancer get stronger before surgery. About 22 participants will follow the program to see if they can stick with it. The goal is to improv…

This study looks at whether timed fasting (not eating for 16 hours a day, 5 days a week) is safe and doable for women getting chemotherapy before ovarian cancer surgery. Researchers want to see if it can improve quality of life and reduce side effects compared to a standard diet.…

This study aims to understand why some ovarian cancers become resistant to platinum-based chemotherapy. Researchers will follow 600 patients for 5 years, collecting medical data and biological samples (blood, tumor, and fluid samples) during standard care. No extra procedures are…

This study is collecting blood samples from 300 people with ovarian cancer to find immune markers that might predict how the disease will progress. Researchers will look at certain immune cells to see if they are linked to survival. No new treatment is given; the goal is to learn…

This study looks at the immune system in people newly diagnosed with epithelial ovarian cancer. Researchers will collect tumor tissue, blood, and other samples to see which immune cells are present and how they relate to how long the cancer stays under control. The goal is to lea…